[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-neoplasm":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,59,94,144,176,203,231,253],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100641147","digitally-supported-prehabilitation-before-major-visceral-cancer-surgery-100641147",false,"NCT07658313","Digitally Supported Prehabilitation Before Major Visceral Cancer Surgery","From Prehabilitation to Rehabilitation: A Feasibility Trial for Digitally Supported Prehabilitation in Major Visceral Oncologic Surgery","P2R-OncoVis","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Clinical diagnosis requiring major surgery of the pancreas, liver, bile ducts, stomach, or esophagus with curative intent\n* Confirmed indication for surgery by the multidisciplinary tumor board\n* Medical stability and physician clearance to participate in a prehabilitation exercise program\n* Willingness and ability to attend center-based prehabilitation exercise sessions three times per week, or once per week with additional tele-prehabilitation if travel time exceeds 40 minutes one way\n* Willingness and ability to perform home-based physical activities\n* Sufficient German language proficiency and digital literacy\n* Access to a smartphone or tablet device with internet connection\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Physical disability or mental impairment preventing safe participation in the study\n* Health care medical power of attorney not permitting independent consent\n* Non-elective, emergency, or revision surgery\n* Acute medical condition contraindicating participation in a structured prehabilitation program","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Major visceral oncologic surgery is associated with high postoperative morbidity, prolonged hospitalization, delayed recovery, and reduced quality of life. Patients undergoing surgery of the pancreas, liver, bile ducts, stomach, or esophagus frequently present with reduced physical fitness, malnutrition, sarcopenia, and psychological distress, all of which may negatively affect surgical outcomes and rehabilitation. Although prehabilitation has shown potential to improve functional capacity before surgery, structured prehabilitation pathways are currently not routinely implemented in Austria, and the feasibility of digitally supported perioperative care pathways remains insufficiently evaluated.\n\nThe aim of the Prehab2Rehab-OncoVis study is to evaluate the feasibility, acceptability, and safety of a multimodal, digitally supported prehabilitation intervention for patients undergoing major visceral oncologic surgery with curative intent. The study will additionally explore potential effects on clinical recovery, functional capacity, rehabilitation outcomes, and patient-reported outcomes across the perioperative pathway.\n\nPrehab2Rehab-OncoVis is designed as a prospective, single-arm feasibility cohort study conducted at the University Hospital Salzburg and the University Institute of Sports Medicine, Prevention and Rehabilitation, coordinated by the Paracelsus Medical University in cooperation with the Ludwig Boltzmann Institute for Rehabilitation Research and the Ludwig Boltzmann Institute for Digital Health and Prevention within the Prehab2Rehab consortium. Approximately 30 adult patients, with the possibility to include up to 50 participants if feasible, will be consecutively recruited.\n\nThe intervention consists of a four-week multimodal prehabilitation program combining supervised exercise training, promotion of physical activity, nutritional counseling, psycho-oncological distress screening, and health literacy support. Digital tools will support the intervention throughout the perioperative pathway, including the HERO application (Das Herz Reha-Informationstool) for patient education and health literacy, aktivplan as a digital exercise planner and training diary, and the CAATS telecommunication platform for remote supervision and tele-prehabilitation sessions where appropriate.\n\nThe exercise intervention includes supervised center-based sessions and, for participants with longer travel distances, a hybrid model combining center-based and tele-prehabilitation sessions. Nutritional counseling will follow current European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines and includes screening for malnutrition risk. Psycho-oncological distress screening will follow recommendations of the German Cancer Society and includes referral to supportive care when clinically indicated.\n\nParticipants will be assessed throughout the perioperative pathway, including at the beginning and end of prehabilitation (Prehabilitation Assessment 1 \\[PRE1\\] and Prehabilitation Assessment 2 \\[PRE2\\]), during hospitalization and rehabilitation, and at a three-month follow-up after surgery. Primary outcomes focus on feasibility, including recruitment and retention rates, adherence, fidelity, safety, data management feasibility, and acceptability and usability of the digital technologies. Secondary outcomes include clinical recovery indicators, postoperative complications, length of hospital and intensive care stay, functional independence, psychological well-being, quality of life, body composition, cardiorespiratory fitness, functional exercise capacity, and muscle strength.\n\nTo contextualize outcomes, two historical comparator cohorts will be used: a local hospital cohort of patients who previously underwent similar surgery without prehabilitation, and a national rehabilitation cohort derived from routine rehabilitation datasets matched for diagnosis, sex, and age.\n\nThe study is intended to generate feasibility data and preliminary estimates that may support the development of future adequately powered randomized controlled trials evaluating digitally supported prehabilitation and rehabilitation pathways in visceral oncologic surgery.",[27,28,29,30,31,32,33,34,35],"Gastrointestinal Neoplasms","Pancreatic Neoplasms","Liver Neoplasm","Oesophageal Cancer","Gastrointestinal Cancer","Pancreatic Cancer","Liver Cancer","Prehabilitation","Cancer Rehabilitation",[34,37,38,39,40,41,42,43,44,45],"Visceral Surgery","Oncology","Rehabilitation","Digital Health","Exercise Therapy","Teleprehabilitation","Cancer Surgery","Preoperative Care","Functional Recovery","NOT_YET_RECRUITING","2026-06-16",{"date":49,"type":50},"2026-06-18","ACTUAL",{"date":52,"type":21},"2026-06",{"date":54,"type":21},"2027-07",{"name":56,"class":57},"Ludwig Boltzmann Institute for Digital Health and Prevention","OTHER",2,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100618701","prediction-model-for-mins-after-major-hepatobiliary-surgery-100618701","NCT07335042","Prediction Model for MINS After Major Hepatobiliary Surgery","Development of an Interpretable Prediction Model for Myocardial Injury After Noncardiac Surgery in Patients Undergoing Major Hepatobiliary Surgery","Inclusion Criteria:\n\nAdults (18-85 yr, ASA physical status II-III) undergoing major hepatobiliary surgery were enrolled. Major surgery was defined as duration ≥ 3 h involving hepatectomy (≥ 3 segments) or biliary reconstruction necessitating ICU admission. Eligibility required paired perioperative high-sensitivity cardiac troponin T (hs-cTnT) data and comprehensive documentation of surgical covariates, including surgical approach (laparoscopic vs. open), resection nature (anatomic vs. non-anatomic), number of resected segments, tumor characteristics (size and location), and presence of cirrhosis.\n\nExclusion Criteria:\n\n(1) preoperative acute myocardial infarction, unstable angina, heart failure, or chronic kidney disease (estimated glomerular filtration rate \\\u003C 60 ml\u002F (min · 1.73 m2); (2) undocumented inflow occlusion strategy; or (3) non-imputable missing covariates.","85 Years",{"count":68,"type":21},1800,"OBSERVATIONAL","This multi-center, prospective observational study aims to develop and validate an interpretable prediction model for Myocardial Injury After Noncardiac Surgery (MINS) in patients undergoing major hepatobiliary surgery. The study adopts a nested modeling strategy, starting with baseline risk factors (e.g., RCRI) and stepwise incorporating hepatic inflow occlusion strategies (specifically comparing SPVO vs. Pringle maneuver) and routine intraoperative biomarkers. The model's performance will be evaluated using AUC, Net Reclassification Improvement (NRI), and Decision Curve Analysis (DCA), followed by interpretability analysis using SHAP values and external validation in an independent cohort.",[72,73,29,74],"Myocardial Injury After Noncardiac Surgery (MINS)","Postoperative Complications","Hepatobiliary Diseases",[76,77,78,79,80,81,82],"MINS","Major Hepatobiliary Surgery","Hepatectomy","Hepatic Inflow Occlusion","Pringle Maneuver","Prediction Model","High-sensitivity Cardiac Troponin","RECRUITING","2026-06-12",{"date":86,"type":50},"2026-06-15",{"date":88,"type":50},"2026-01-14",{"date":90,"type":21},"2027-06-30",{"name":92,"class":57},"Beijing Tsinghua Chang Gung Hospital",6,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":105,"conditions":106,"keywords":111,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":141,"locationsCount":143},"100604152","phase-2-y-90-treatment-response-using-transarterial-radioembolization-100604152","NCT07145801","Y-90 Treatment Response Using Transarterial Radioembolization","Contrast-Enhanced Ultrasound Evaluation of Radioembolization Treatment Response","TARE","Inclusion Criteria:\n\n* Scheduled for TARE therapy of a treatment naïve HCC visible on ultrasound.\n* Be at least 18 years of age.\n* Be medically stable.\n* If a female of child-bearing age, must have a negative pregnancy test.\n* Have signed Informed Consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable.\n* Patients with known sensitivities to the components of Lumason.\n* Patients with known sensitivities to the components of Sonazoid.",{"count":20,"type":21},[104],"PHASE2","This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE). HCC is the third leading cause of cancer mortality worldwide and the single fastest growing cause of cancer mortality in the United States. TARE is recommended for 15-25% of HCC patients. Treatment response is generally evaluated using contrast-enhanced CT or MRI 1-2 months and 4-6 months post-TARE. Although TARE is an effective therapy, assessment of treatment response using CT\u002FMRI is challenging because CT\u002FMRI frequently diagnoses tumor response as equivocal or non-progressing for up to 6 months post-TARE based on LI-RADS criteria. This delay in diagnosing tumor viability subsequently delays needed retreatment and can even serve as a barrier to transplantation. Our prior work in HCC locoregional therapy has shown CEUS provides improved sensitivity in detecting viable tumor following transarterial chemoembolization relative to traditional CT\u002FMRI. Therefore, the investigators propose to evaluate both qualitative and quantitative CEUS as a tool for evaluating HCC post-TARE at similar time points of clinically recommended cross-sectional imaging, while also investigating the role of Kupffer phase imaging.\n\nThe investigators plan to enroll a total of 30 patients scheduled for TARE of a treatment naïve HCC over an 18-month period, allowing for a minimum of 6 months follow up. Patients will undergo a CEUS examination within two weeks of their first two clinically indicated CT\u002FMRI exams (obtained at Jefferson 1-2 months and 4-6 months post TARE). In patients retreated prior to their 4-6 month MRI, CEUS may also be performed in the absence of the MRI at this time point but prior to retreatment. Patients will be recruited across six major hospitals within the Jefferson Health Enterprise. Those eligible for participation will be identified by project co-investigators and contacted by the study coordinator to discuss participation and to explain the study. The patient will be given time to consider the risks and benefits of the study and ask questions about participation. If agreeable, the patient will then arrange with the project coordinator to come to Jefferson's center city campus to sign consent and take part in the research study.",[107,108,33,109,110,29],"HCC","Hepatocellular Carcinoma","Hepatic Neoplasm","Primary Liver Cancer",[112,100,113,114,115,116,107,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134],"transarterial radioembolization","CEUS","contrast-enhanced ultrasound","hepatocellular","carcinoma","hepatocellular carcinoma (HCC)","liver cancer","liver tumors","liver lesions","microbubbles","liver parenchyma","liver imaging","HCC locoregional therapy","Ultrasound","Kupffer","Yttrium-90","tumor viability","time intensity curves","parametric maps","microbubble destruction","bolus contrast injection","CEUS biomarker","Y90 TARE","2026-06-08",{"date":137,"type":50},"2026-06-10",{"date":139,"type":50},"2025-09-11",{"date":90,"type":21},{"name":142,"class":57},"Thomas Jefferson University",1,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":5},"100428822","phase-1-gpc3-targeted-t-cell-therapy-ect204-in-adults-with-advanced-hcc-100428822","NCT04864054","GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC","An Open-Label, Dose Escalation, Multi-Center Phase I\u002FII Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC)","ARYA-3","Inclusion Criteria:\n\n* Histologically confirmed HCC, that is unresectable, recurrent, and\u002For metastatic.\n* GPC3-positive tumor expression confirmed by immunohistochemistry (IHC).\n\n  * For the dose-escalation cohort: ≥10-20% tumor cells, ≥2+ IHC.\n  * Beginning with the RP2D confirmatory cohort: ≥ 50% tumor cells, 2+\u002F3+ IHC.\n* Must have received at least first-line systemic therapy for HCC and have experienced disease progression on, or intolerance to, that therapy.\n* Life expectancy of at least 4 months per the Investigator's opinion.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Measurable disease by RECIST v1.1.\n* Child-Pugh score of A6 or better.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* Pre-existing illness (e.g., symptomatic congestive heart failure) that would limit compliance with study requirements.\n* Active, uncontrolled systemic bacterial, fungal, or viral infection. Subjects with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C are eligible provided their infection is being treated and the viral load is controlled.\n* History of malignancy other than HCC within 5 years before screening, except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other malignancies with low risk of recurrence.\n* Known brain metastases or other active central nervous system (CNS) involvement, including leptomeningeal disease. Subjects with brain metastases that have been adequately treated (no evident neurological deficit and no steroid or anti-epileptic therapy for brain metastases) are eligible.\n* Pregnant or lactating women.\n* Currently receiving or ending (\\\u003C 14 days from date of consent) liver tumor-directed therapy (e.g., radiation, ablation, embolization), or hepatic surgery.\n* Concurrently receiving other investigational agents, biological, chemical, or radiation therapies, while participating in the study.\n* Active autoimmune disease requiring systemic immunosuppressive therapy.\n* Presence of portal vein tumor thrombus (PVTT) classified as grade Vp4, or any invasion into the inferior vena cava (IVC), except for subjects with IVC invasion who have been treated and radiographically stable for at least 6 months prior to screening.\n* Ascites requiring active treatment, such as a requirement for paracentesis or escalation of diuretic doses. Exception: Subjects maintained on a stable dose of diuretics with controlled, asymptomatic ascites are eligible.\n* Active gastrointestinal (GI) bleeding event ≥ Grade 3 per National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE), version 5.0, within 6 months prior to screening.\n* Coagulation abnormality defined as international normalized ratio (INR) \\> 1.7, unless the elevation is due to therapeutic anticoagulation that, in the Investigator's judgment, can be safely managed in the context of study procedures.\n* History of organ transplant.\n* HCC involving greater than 50% of the liver volume.\n* Experienced allergies to any component of the study drug (ECT204), mouse immunoglobulin, or iron-dextran, or have a history of severe hypersensitivity, including anaphylaxis.\n* Previously received other gene therapy (e.g., chimeric antigen receptor T-cell \\[CAR-T\\] therapy); exception: prior oncolytic virus therapy is permitted.).\n* Contraindication for undergoing leukapheresis procedure or receipt of conditioning agents",{"count":153,"type":21},60,[155,104],"PHASE1","This is an open-label, multi-center, Phase 1\u002F2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, or intolerance to, prior systemic therapy.",[108,158,29,159],"Liver Cancer, Adult","Metastatic Liver Cancer",[108,161,162,33,29,159,163,164,165,107],"Advanced HCC","Late-Stage HCC","Metastatic HCC","T-cell therapy","Immunotherapy","2026-06-05",{"date":168,"type":50},"2026-06-09",{"date":170,"type":50},"2022-03-11",{"date":172,"type":21},"2027-12-31",{"name":174,"class":175},"Eureka Therapeutics Inc.","INDUSTRY",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":185,"conditions":186,"keywords":187,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100452259","radio-opaque-contrast-agents-for-liver-cancer-targeting-with-kim-during-radiation-therapy-100452259","NCT05169177","Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy","ROCK-RT","Inclusion Criteria:\n\n* Received or will receive stereotactic ablative body radiotherapy (SABR) treatment for liver cancer at a participating site.\n* Received a radio-opaque contrast agent (e.g. Lipiodol™ or DC Bead LUMI™) that is visible on the radiation treatment planning CT scan\n* The radio-opaque contrast agent mass is or will be within the x-ray imaging field of view during the CBCT scan and any planned intra-fraction imaging. Note that there is no requirement of the distance between the contrast agent mass and the treated tumour as the goal of the study is the contrast agent mass tracking.\n* Provides written informed consent (prospectively recruited) or meets criteria for waiving of the requirement for consent (retrospectively recruited)\n\nExclusion Criteria:\n\n* Less than 18 years of age\n* Minimum image dataset is not available\n* Image dataset is not in a compatible format",{"count":184,"type":21},50,"This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detected by tumour-tracking software (KIM).",[29],[188,189,190,191,192],"Radiation Therapy","Stereotactic Ablative Body Radiation Therapy","SABR","Kilovoltage intrafraction monitoring","Radio opaque contrast","2026-05-15",{"date":195,"type":50},"2026-05-19",{"date":197,"type":50},"2022-10-17",{"date":199,"type":21},"2026-10-31",{"name":201,"class":57},"University of Sydney",5,{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":209,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":210,"targetDuration":212,"studyType":69,"phases":4,"briefSummary":213,"conditions":214,"keywords":218,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":143},"100613358","single-cell-multiomics-and-spatiotemporal-omics-analyze-the-mechanism-of-liver-degenerative-disease-100613358","NCT07265544","Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease","Inclusion Criteria:\n\n1. Voluntarily signed the informed consent form;\n2. No restrictions on age and gender;\n3. Patients diagnosed with hepatic hemangioma or focal nodular hyperplasia of the liver in accordance with the \"Guidelines for the Diagnosis and Treatment of Focal Liver Lesions (2014 Edition)\" and the \"Guidelines for the Diagnosis and Treatment of Hemangiomas and Vascular Malformations (2019 Edition)\";\n4. Patients with hepatic hemangioma, focal nodular hyperplasia of the liver, fatty liver, HBV infection, liver fibrosis, and cirrhosis who clinically require liver surgery or liver biopsy.\n\nExclusion Criteria:\n\n1. Individuals with concurrent infections such as HIV will be excluded.\n2. Patients with coagulation system disorders, such as hemophilia or idiopathic thrombocytopenic purpura, will not be included.\n3. Those with severe underlying diseases that affect the body's immune status will be excluded.\n4. Individuals whom the investigator deems unsuitable for participation in this study will be excluded.",true,{"count":211,"type":21},240,"7 Days","The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma, focal nodular hyperplasia, liver fibrosis, cirrhosis, and HBV infection. The primary questions it aims to address are:\n\nInvestigate the mechanisms of liver degenerative changes during the processes of liver aging, fatty liver, HBV infection, liver fibrosis, and cirrhosis.\n\nCharacterize the molecular features and cellular networks at different stages of liver degeneration and identify new targets and mechanisms for the cure of the aforementioned diseases.\n\nThe study will collect peripheral blood and discarded liver tissue from patients with hepatic hemangioma, fatty liver, HBV infection, liver fibrosis, and cirrhosis who are undergoing hepatectomy or liver biopsy.",[29,215,216,217],"HBV Infection","Non-alcoholic Fatty Liver Disease NAFLD","Liver Fibrosis",[219,220,221],"single-cell multi-omics","HBV infection","liver degenerative changes","2026-04-13",{"date":224,"type":50},"2026-04-14",{"date":226,"type":50},"2023-03-01",{"date":228,"type":21},"2027-02-12",{"name":230,"class":57},"Nanfang Hospital, Southern Medical University",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":143},"100624746","variability-of-microwave-ablation-volume-based-on-clinical-radiological-biological-and-tissue-factors-100624746","NCT07413640","Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors","Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors : a Retrospective Study","MICRO-VAR","Inclusion Criteria:\n\n* Adult patients\n* Treated with percutaneous hepatic microwave ablation under CT or ultrasound guidance\n* Adult treated for one or more liver lesions\n* Patients with available follow-up imaging\n\nExclusion Criteria:\n\n* Two treatment cycles on the same lesion during the same session.\n* Reoperation on the same lesion.\n* Planned volume not available (no manufacturer data, not specified in the surgical report).\n* No control imaging injected between 1 and 4 months post-procedure.\n* Final ablation volume not measurable (e.g., artifacts, no injection on MRI).\n* No definitive diagnosis of the nature of the tumor on imaging and no histology available.","100 Years",{"count":241,"type":21},90,"Microwave ablation is a minimally invasive technique whose planning relies on manufacturer tables derived from ex vivo models that do not account for patient or tumor-specific factors. In clinical practice, the actual ablation volume often differs from the planned volume due to liver characteristics, vascular proximity, and tumor biology.\n\nThis study aims to assess the variability between ablation small axis during percutaneous microwave ablation of liver lesions. The influence of patient-related (fibrosis, steatosis, portal flow) and tumor-related factors (location, histology, prior treatment) will be evaluated. Small axis and volume will be compared with volumes measured on immediate post-procedural CT and on CT\u002FMRI at 6-12 weeks, accounting for expected tissue shrinkage.",[29],"2026-02-24",{"date":246,"type":50},"2026-02-25",{"date":248,"type":50},"2026-02-02",{"date":250,"type":21},"2026-07-01",{"name":252,"class":57},"Central Hospital, Nancy, France",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":143},"100558736","phase-3-debiri-plus-chemotherapy-vs-chemotherapy-alone-in-colorectal-cancer-liver-metastases-100558736","NCT06555003","DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases","Comparative Analysis of the Efficacy of Irinotecan-loaded Drug-eluting Beads (DEBIRI) in Combination With Systemic Chemotherapy Versus Chemotherapy Alone in Unresectable Colorectal Cancer Liver Metastases: a Randomized Clinical Trial","CLEAR-DEBIRI","Inclusion Criteria:\n\n* unresectable\u002Fborderline resectable colorectal cancer liver metastases, chemotherapy-naïve for metastatic disease, Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less adequate hematologic, hepatic, and renal function ( absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL, platelet ≥ 75 ×10\\^9\u002FL, international normalized ratio ≤ 1.3, Total bilirubin ≤ 2.0 mg\u002FdL, aspartate aminotransferase and alanine aminotransferase ≤ 5 × the upper limit of normal (ULN), Albumin ≥ 2.5 g\u002FdL, Creatinine ≤ 2.0 mg\u002FdL)\n\nExclusion Criteria:\n\n* candidates for curative surgery without the need for neoadjuvant therapy, Liver involvement of ≥ 70%, brain metastases or Peritoneal carcinomatosis, cirrhosis, presence or History of an allergic reaction to any of the study drugs Chronic viral hepatitis B or C",{"count":262,"type":21},116,[264],"PHASE3","A total of 116 patients who meet the inclusion criteria and are chemotherapy-naïve for their metastatic disease, will be randomly assigned to either the treatment group (DEBIRI plus systemic chemotherapy) or the control group (systemic chemotherapy alone).\n\nAfter 4 cycles of chemotherapy and 2 cycles of DEBIRI, patient reassessment to evaluate treatment response, based on RECIST criteria, will be performed using MRI or CT scan within 1-3 months of treatment initiation.\n\nThe feasibility of secondary tumor resection, as primary endpoint, will be reassessed at a three-month follow-up multidisciplinary team (MDT) meeting, guided by established clinical guidelines.",[29,267],"Colorectal Cancer Metastatic",[269,270,271,272,273],"irinotecan loaded drug-eluting beads TACE (DEBIRI-TACE)","colorectal liver metastases","survival","irinotecan","chemoembolization","2025-04-17",{"date":276,"type":50},"2025-04-23",{"date":278,"type":50},"2025-01-20",{"date":280,"type":21},"2027-12",{"name":282,"class":57},"Tehran University of Medical Sciences"]